Biocryst Pharmaceuticals diskutieren
Biocryst Pharmaceuticals
WKN: 896047 / Symbol: BCRX / Name: Biocryst Pharm / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
8,11 €
1,19 %
BioCryst Pharmaceuticals (BCRX) had its price target lowered by Needham & Company LLC from $18.00 to $16.00. They now have a "buy" rating on the stock.
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals (BCRX) had its price target lowered by Wedbush from $22.00 to $21.00. They now have an "outperform" rating on the stock.
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals (BCRX) had its price target raised by Cantor Fitzgerald from $27.00 to $29.00. They now have an "overweight" rating on the stock.
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals (BCRX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $32.00 price target on the stock.
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals (BCRX) had its price target raised by Royal Bank Of Canada from $13.00 to $14.00. They now have an "outperform" rating on the stock.
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals (BCRX) had its price target lowered by Wedbush from $21.00 to $20.00. They now have an "outperform" rating on the stock.
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals (BCRX) had its price target lowered by Royal Bank Of Canada from $14.00 to $13.00. They now have an "outperform" rating on the stock.
Ratings data for BCRX provided by MarketBeat
Neueste Beiträge
Citigroup_Inc_ in Serco Group plc diskutieren